Lung Cancer | Specialty

Immuno-Oncology Combination Therapy: Which Patients With NSCLC?

March 1st 2018

Pembrolizumab + Chemotherapy in Newly Diagnosed NSCLC

March 1st 2018

Checkpoint Inhibitors for Newly Diagnosed Stage 4 NSCLC

March 1st 2018

Potential for Use of Checkpoint Inhibitors in Early-Stage NSCLC

March 1st 2018

Surgery in the Context of Immunotherapy for Locally Advanced NSCLC

March 1st 2018

Treatment of Unresectable Locally Advanced NSCLC

March 1st 2018

Treatment of Operable Locally Advanced NSCLC

March 1st 2018

Interest Builds in Targeting MET Mutations in Non-Small Cell Lung Cancer

February 28th 2018

Building on the success of molecularly targeted drugs aimed at relatively small subsets of patients, lung cancer researchers are increasingly aiming at the MET oncogene.

Expert Highlights Immunotherapy Use in Stage III NSCLC

February 28th 2018

Gary Schwartz, MD, discusses the significance of the PACIFIC trial and applications of immunotherapy for patients with stage III locally advanced disease.

Dr. Borghaei Discusses the PACIFIC Trial in Lung Cancer

February 27th 2018

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses the PACIFIC trial in patients with non–small cell lung cancer (NSCLC).

Dr. Ramalingam on Pembrolizumab and Chemotherapy in NSCLC

February 27th 2018

Suresh A. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses data with pembrolizumab (Keytruda) and chemotherapy in patients with non–small cell lung cancer (NSCLC).

Dr. Portnoy on the Importance of Driver Mutations in the Treatment of NSCLC

February 24th 2018

David C. Portnoy, MD, medical oncologist and hematologist, West Cancer Center, discusses the importance of driver mutations in the treatment of non–small cell lung cancer (NSCLC).

Ramalingam Highlights Immunotherapy Advances in NSCLC

February 23rd 2018

Suresh A. Ramalingam, MD, discusses the exciting findings from the KEYNOTE-189 and IMpower150 immunotherapy trials in patients with non–small cell lung cancer.

Surgery Remains Imperative in Biomarker-Driven NSCLC Era

February 22nd 2018

David Mason, MD, addresses the evolving role of surgery for patients with non–small cell lung cancer.

Dr. Mason on the Reliability of the PD-L1 Biomarker

February 22nd 2018

David P. Mason, MD, chief, Thoracic Surgery and Lung Transplantation, Baylor Scott & White Center for Thoracic Surgery, discusses the reliability of the PD-L1 biomarker in non–small cell lung cancer (NSCLC) and its potential applications in surgical approaches.

Dr. Konduri Addresses Unanswered Questions in NSCLC

February 22nd 2018

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses lingering questions in patients with non–small cell lung cancer (NSCLC).

Clinical Trials Highlight Biomarker Progress in Lung Cancer

February 22nd 2018

Kartik Konduri, MD, shares insight on molecular developments, recently discussed clinical trials, and steps the field needs to take to continue moving in a biomarker-driven paradigm of non–small cell lung cancer treatment.

Dr. Levy Discusses the FLAURA Study in Lung Cancer

February 22nd 2018

Benjamin P. Levy, MD, assistant professor of oncology, clinical director of medical oncology, Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins Medicine, discusses the FLAURA study in patients with lung cancer.

Simon Shares Insight on Emerging Immunotherapy Regimens in NSCLC

February 21st 2018

George R. Simon, MD, discusses emerging advancements with immunotherapy combination strategies for patients with NSCLC.

ALK Inhibitors Continue to Reshape Treatment in NSCLC

February 20th 2018

Ravi Salgia, MD, PhD, discusses the evolving role of ALK-directed therapies for patients with non-small cell lung cancer.